April 8, 2022

ArmonAir® Digihaler® (fluticasone propionate) has received an expanded indication to provide maintenance treatment (as prophylactic therapy) for asthma in patients who are at least four years old.

  • First approved in 2020, ArmonAir Digihaler was initially indicated for patients at least 12 years The active pharmaceutical ingredient, fluticasone propionate, has been FDA approved since 1994.
  • The FDA also approved a new ArmonAir Digihaler 30mcg dosage strength for the younger pediatric Recommended dosing under the expanded indication is determined by the patient’s age and severity of disease:
    • Patients 12 years and older: One 55mcg, 113mcg, or 232mcg dose taken twice daily by oral inhalation.
    • Patients 4-11 years old: One 30mcg or 55mcg dose taken twice daily by oral inhalation.
May 1, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in May

Read More
April 25, 2022

Veklury Approved to Treat COVID-19 in Younger Patient Population

Read More
April 22, 2022

Pfizer Recalls Five Lots of Accupril

Read More
April 21, 2022

Zerbaxa Now Indicated for Children

Read More